Clinical Trials Sponsored by Mytrus

Total 2813 results

Bristol-Myers Squibb

Withdrawn

Japanese Bridging Study Conducted in the United States

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation

Hepatitis B

United States, France, India, Taiwan, Thailand, Turkey, United Kingdom, Brazil, Canada, Poland, Russian Federation, Singapore, Greece, South Africa, Hong Kong, Philippines, Indonesia
Bristol-Myers Squibb

Withdrawn

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Atherosclerotic Cardiovascular Disease
Bristol-Myers Squibb

Terminated

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Neoplasm Metastasis | Colorectal Cancer

United States, Canada
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

HIV

United States
Bristol-Myers Squibb

Completed

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction (PK)

Chronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus Infection

United States
Bristol-Myers Squibb

Completed

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) (MDX1342-02)

Chronic Lymphocytic Leukemia

United States
Bristol-Myers Squibb

Completed

Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer. (MDX1411-01)

Kidney Cancer

United States
Bristol-Myers Squibb

Completed

Comparative Tolerability of Protease Inhibitors

HIV
Bristol-Myers Squibb

Terminated

Belatacept in Liver Transplant Recipients

Immunosuppression in Solid Organ Transplant

France, Germany, Italy, United States, Austria, Canada, Spain, Argentina, Brazil
Bristol-Myers Squibb

Completed

A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects

Healthy
Bristol-Myers Squibb

Completed

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects (INX-189-004)

Healthy

United States
Bristol-Myers Squibb

Completed

Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin (NHV)

Healthy Volunteers

Australia
Bristol-Myers Squibb

Completed

Abatacept With Methotrexate- Phase IIB

Rheumatoid Arthritis

Belgium, United States, Canada, Germany, United Kingdom, Australia, France, Ireland, Netherlands, Argentina, South Africa
Bristol-Myers Squibb

Completed

Study of MDX-010 in Stage IV Breast Cancer

Adenocarcinoma | Breast Cancer

United States
Bristol-Myers Squibb

Completed

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Netherlands, Spain, United States, Italy, Canada, France, Germany, Peru, Singapore, United Kingdom, Australia, Sweden, Finland, Israel, Ireland, Denmark, Korea, Republic of, Norway, Austria, South Africa, Switzerland
Bristol-Myers Squibb

Withdrawn

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (PD-L1)

Stage III or IV Melanoma
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Neoplasms

Japan
Bristol-Myers Squibb

Completed

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients

HIV Infections

United States, Puerto Rico
Bristol-Myers Squibb

Completed

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

HIV Infections

United States
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
Bristol-Myers Squibb

Completed

Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents

Rheumatoid Arthritis
Bristol-Myers Squibb

Completed

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Carcinoma, Hepatocellular

United States, Spain
Bristol-Myers Squibb

Completed

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

HIV Infections

United States, Canada, Belgium, Mexico, Italy, France, Argentina, Israel, Spain, Brazil, Puerto Rico, Australia, Portugal, Russian Federation, South Africa, Thailand
Bristol-Myers Squibb

Completed

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

HIV Infections

United States, Canada
Bristol-Myers Squibb

Completed

Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease

Hypercholesterolemia
Bristol-Myers Squibb

Completed

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Bristol-Myers Squibb

Completed

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

HIV Infections

United States, Canada
Bristol-Myers Squibb

Completed

Phase I (PH I) Mad Refractory Solid Tumor Study

Neoplasms

United States, United Kingdom
Bristol-Myers Squibb

Completed

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

Diabetes Mellitus, Non-Insulin-Dependent

United States
Bristol-Myers Squibb

Completed

A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Bristol-Myers Squibb

Completed

Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)

Actue Coronary Syndromes
Bristol-Myers Squibb

Completed

A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

Chronic Hepatitis B

United States
Bristol-Myers Squibb

Completed

A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.

HIV Infections

United States
Bristol-Myers Squibb

Completed

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

HIV Infections

United States
Bristol-Myers Squibb

Completed

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

Chronic Hepatitis B

United States
Bristol-Myers Squibb

Completed

Drug Interaction - Oral Contraceptive

HIV Infections

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Bristol-Myers Squibb

Completed

Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Bristol-Myers Squibb

Completed

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

HIV Infections

United States
Bristol-Myers Squibb

Completed

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

HIV Infections | Protease Inhibitor

United States
Bristol-Myers Squibb

Completed

Atazanavir Twice Daily

HIV Infections | Protease Inhibitor

United States
Bristol-Myers Squibb

Completed

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-816336 in Healthy Male Subjects

Dyslipidemia | Diabetes Mellitus, Non-Insulin-Dependent

Australia
Bristol-Myers Squibb

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

Alzheimer's Disease

United States
Bristol-Myers Squibb

Terminated

Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

Atherosclerosis | Hypercholesterolemia

Germany
Bristol-Myers Squibb

Completed

Multiple Dose Japanese Bridging Study

Alzheimer Disease

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

Australia

3

Subscribe